For research use only. Not for therapeutic Use.
JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM)[1].JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death[2].
JR-AB2-011 (10 µM – 250 µM; 48h) significantly reduces the survival rate and proliferation ability of different melanoma cell lines (MelJu, MelJuso, MelIm, B16)[2].
JR-AB2-011 (50 µM, 250 µM; 48 h) decreases the phosphorylation level of Akt in MelIm cells, indicating that inhibition of mTORC2 attenuated the Ak t signaling pathway[2].
JR-AB2-011 (50 µM, 250 µM; 48-78 h) results in a significant decrease in cell survival fraction SF and a significant reduction in the migration and invasive ability of melanoma cells, which is mainly achieved by decreasing MMP2 activity[2].
JR-AB2-011 (20 mg/kg; i.p.; daily) reduces the size and number of liver metastases in C57BL/6N mice with injection of B16 cells. No severe side effects or weight loss[2].
JR-AB2-011 (4 mg/kg; p.o.; daily) significantly blocks the Dioscin-induced promotion of M2 macrophage polarization[3].
| Catalog Number | I019310 |
| CAS Number | 2411853-34-2 |
| Synonyms | N-(3,4-dichlorophenyl)-2-(4-fluorophenyl)imino-5-methyl-1,3-thiazolidine-3-carboxamide |
| Molecular Formula | C17H14Cl2FN3OS |
| Purity | ≥95% |
| InChI | InChI=1S/C17H14Cl2FN3OS/c1-10-9-23(16(24)21-13-6-7-14(18)15(19)8-13)17(25-10)22-12-4-2-11(20)3-5-12/h2-8,10H,9H2,1H3,(H,21,24) |
| InChIKey | SHKNIJKASRGSEG-UHFFFAOYSA-N |
| SMILES | CC1CN(C(=NC2=CC=C(C=C2)F)S1)C(=O)NC3=CC(=C(C=C3)Cl)Cl |
| Reference | [1]. Zhang A, et al. CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats. Stroke Vasc Neurol. 2022 Jul 26;8(1):4–16. [2]. Guenzle J, et al. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int J Mol Sci. 2020 Dec 22;22(1):30 [3]. Wu M, et al Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. 2021 Oct ; 172:105796 |
